Glioma is a broad category of brain and spinal cord tumors that comes from glial cells. Malignant gliomas, the most common subtype of primary brain tumors, are aggressive, highly invasive, and neurologically destructive tumors considered to be among the deadliest of human cancers. In its most aggressive manifestation, glioblastoma (GBM), median survival ranges from 9 to 12 months. The overall annual incidence of gliomas is in the range of 5–6/100,000.

Current treatment options include surgery, radiation, and chemotherapy. Surgery combined with radiotherapy and chemotherapy has proven to prolong patient survival. However, patients diagnosed with malignant glioma who are treated with traditional therapeutic methods often experience harmful side effects like loss of cognitive process from surgery, inflammatory responses from chemotherapy or even induction of secondary cancers from radiation therapy. No one of current methods is able to completely cure the disease.

There are several novel approaches to treatment of glioma:

• Conditional cytotoxic approaches introduce noncytotoxic enzymes into the glioma which upon prodrug administration convert the prodrugs into toxic compounds capable of killing tumors
• Anti-angiogenic paradigms are designed to prevent the vascularization of tumors which is required for growth and metastasis;
• Immune stimulatory approaches seek to use the patient’s own immune system to target and destroy tumors
• Targeted toxin strategies utilize receptors specifically overexpressed on glioma cells to target the toxins directly into tumor cells, specifically destroying these cells
• Tumor suppressors and oncogenes are targets for gene therapy and utilize the genetic abnormalities of the tumor as a therapeutic target

Most of novel methods use molecular biomarkers of glioma. But there is lack in biomarkers' databases. This database accumulates receptor biomarkers of glioma.